ヒトマイクロバイオーム市場：製品（医薬品、プロバイオティクス、プレバイオティクス）、用途（治療、診断）、疾患（がん、消化器、感染症）、タイプ（ペプチド、生きたバイオ治療製品、FMT） - 2029年までの世界予測

Human Microbiome Market by Product (Drugs, Probiotics, Prebiotics), Application (Therapeutic, Diagnostics), Disease (Cancer, Gastrointestinal, Infectious), Type (Peptide, Live Biotherapeutic Product, FMT) - Global Forecast to 2029

ヒトマイクロバイオーム市場は、予測期間中に36.1%のCAGRで、2023年の3億米ドルから2029年には17億米ドルに達すると予測されます。ヒトマイクロバイオーム市場の成長を促進する主な要因は、個別化医療に対する需... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2023年5月26日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	183	195	英語

日本語のページは自動翻訳を利用し作成しています。

サマリー

ヒトマイクロバイオーム市場は、予測期間中に36.1%のCAGRで、2023年の3億米ドルから2029年には17億米ドルに達すると予測されます。ヒトマイクロバイオーム市場の成長を促進する主な要因は、個別化医療に対する需要の急増であり、自然でホリスティックなアプローチに対する需要の高まりが市場の成長を促進すると期待されています。しかし、微生物の相互作用に関する理解は限られているため、市場の成長はある程度抑制されると予想されます。
ヒトマイクロバイオーム市場は、製品、タイプ、アプリケーション、疾患、地域に基づいてセグメント化されています。
"用途別では、治療薬分野がヒトマイクロバイオーム市場で最大のシェアを占めている"
アプリケーションに基づき、ヒトマイクロバイオーム市場は、治療薬、診断薬に分類されます。治療薬セグメントは、マイクロバイオームが人間の健康維持に果たす重要な役割に対する理解の高まりにより、2023年の市場を支配しています。また、製薬会社やバイオテクノロジー企業からの投資の増加や、個別化医療への需要の高まりも、この市場を牽引しています。
"疾患別では、感染症分野がヒトマイクロバイオーム市場で最大のシェアを占めている"
疾患別に、ヒトマイクロバイオーム市場は、感染症、内分泌・代謝疾患、消化器疾患、がん、その他の疾患に分類されます。2023年、ヒトマイクロバイオーム市場では、感染症分野がより大きなシェアを占めています。この市場セグメントの成長は、人間の健康におけるマイクロバイオームの役割に対する理解の高まりと、高度なシーケンスおよびバイオインフォマティクス技術の開発により、感染症の予防と治療のための新しいマイクロバイオームベースの治療薬の発見と特徴付けに道が開かれたことに起因していると考えられます。

"北米：ヒトマイクロバイオーム市場の最大シェア"
ヒトマイクロバイオーム市場で最大のシェアを占めたのは、北米です。北米地域の大きなシェアは、この地域のヘルスケアおよびバイオテクノロジー産業が確立されており、高度なインフラ、最先端の研究機関、マイクロバイオーム研究に特化したバイオテクノロジー企業やCROの強力なエコシステムがあることに起因すると考えられます。北米には、マイクロバイオーム研究に特化したプログラムや専門知識を持つ一流の学術機関、研究病院、民間企業が存在し、ヒトマイクロバイオーム市場の成長に寄与しています。
"アジア太平洋地域ヒトマイクロバイオーム市場で最も成長する地域"
アジア太平洋地域のヒトマイクロバイオーム市場は、予測期間中、最も高いCAGRで成長すると予測されています。これは、健康と病気におけるマイクロバイオームの重要性に対する認識の高まり、個別化医療に対する需要の高まり、シーケンス技術の進歩などに起因しています。アジア太平洋地域のヒトマイクロバイオーム市場のもう一つの主要な促進要因は、この地域の人口が多く、急速に高齢化が進んでいることです。
本レポートのために実施した一次インタビューは、以下のように分類されます：

- 回答者別回答者別：供給側60％、需要側40
- 指定者別経営者：40％、研究者：30％、管理職：30
- 国別北米22％、欧州42％、アジア太平洋地域11％、その他の地域25

主なプレイヤー
- セレス・セラピューティクス社（米国）/Seres Therapeutics, Inc.
- エンテローム（フランス）
- 4D pharma plc（英国）
- インターナショナル・フレーバーズ＆フレグランス・インク（米国）
- オプティバイオティクス・ヘルス・ピーエルシー（英国）
- フェリング・ファーマシューティカルズ（スイス）
- シンロジック社（米国）
- セカンドゲノム社(米国)
- ヴェダンタ・バイオサイエンス社（米国）
- YSOPIA Bioscience（フランス）
- フライトパス・バイオサイエンス社（米国）
- フィンチ・セラピューティクス・グループ社（米国）
- AOBiome Therapeutics（米国）
- BioGaia（スウェーデン）
- Quantbiome, Inc. (dba Ombre)（米国）
- Viome Life Sciences, Inc.（米国）
- BIOHM Health（米国）
- DayTwo（米国）
- アトラスバイオメッド（英国）
- ビオネ・ベンチャーズ・プライベート・リミテッド(インド)
- ルクシアサイエンティフィック（フランス）
- メタビオミクス（米国）
- サン・ジェノミクス（米国）
- シードヘルス（米国）
- グヌビオティック・サイエンシズ（スイス）
調査範囲です：
本レポートは、ヒトマイクロバイオーム市場の詳細な情報を提供します。製品（医薬品、診断検査、プロバイオティクス、プレバイオティクス、その他の製品）、用途（治療、診断）、疾患（感染症、消化器疾患、内分泌・代謝疾患、がん、その他の疾患）、などの異なるセグメントにおける市場規模および今後の成長可能性を推定することを目的としている、内分泌・代謝疾患、癌、その他の疾患）、タイプ（細菌コンソーシアム移植（BCT）/糞便微生物叢移植（FMT）、ペプチド、生きたバイオ治療製品、その他のタイプ）、地域（北米、欧州、アジア太平洋、その他の地域）です。また、主要な市場プレイヤーの会社概要、最近の開発状況、主要な市場戦略とともに、詳細な競合分析も掲載しています。

レポート購入の主なメリット
本レポートは、ヒトマイクロバイオーム市場全体とそのセグメントの収益数の最も近い近似値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競争環境をよりよく理解し、より多くの洞察を得ることで、自社のビジネスをよりよく位置づけ、適切な市場参入戦略を立てることができるようになると考えられます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、トレンド、機会、および課題に関する情報を提供することを可能にします。
本レポートは、以下のポイントに関する洞察を提供します。
- 主要な推進要因（マイクロバイオーム研究のためのマイクロバイオーム産業とアカデミアの共同努力、個別化医療に対する需要の急増、ヒトマイクロバイオームの重要性に対する意識の高まり）、阻害要因（マイクロバイオームの商業化に対する複雑な規制ポリシーの悪影響）の分析、機会（新しいマイクロバイオーム技術に取り組むために協力する主要プレーヤーと小規模な革新的企業の連携の増加、シーケンスとバイオインフォマティクスの進歩）、および課題（マイクロバイオームベースの治療法の低い患者採用率、マイクロバイオーム治療法の開発に伴う複雑さ）がヒトマイクロバイオーム市場の成長に影響を与えている。
- 製品開発/イノベーション：ヒトマイクロバイオーム市場における今後の技術、研究開発活動、新製品発売に関する詳細なインサイトを提供します。
- 市場開発：有利な市場に関する包括的な情報-本レポートでは、さまざまな地域のヒトマイクロバイオーム市場を分析しています。
- 市場の多様化：新製品、未開拓の地域、最近の開発、ヒトマイクロバイオーム市場への投資に関する詳細な情報を提供します。
- 競争力のある評価：Seres Therapeutics, Inc.（米国）、Enterome（フランス）、4D pharma plc（英国）、International Flavors & Fragrances Inc.（米国）、OptiBiotix Health Plc（英国）などの主要企業の市場シェア、成長戦略、サービス提供状況をヒトマイクロバイオーム市場戦略で詳細に評価します。また、本レポートは、動物研究モデル市場の鼓動を理解し、主要な市場促進要因、阻害要因、課題、機会に関する情報を関係者に提供するのに役立ちます。

ページTOPに戻る

1 INTRODUCTION 25
1.1 STUDY OBJECTIVES 25
1.2 MARKET DEFINITION 25
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 26
1.4 YEARS CONSIDERED 26
1.5 CURRENCY 27
1.6 RESEARCH LIMITATIONS 27
1.7 STAKEHOLDERS 27
1.7.1 RECESSION IMPACT 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
FIGURE 1 HUMAN MICROBIOME MARKET: RESEARCH DESIGN 28
2.1.1 SECONDARY DATA 29
2.1.2 PRIMARY DATA 29
FIGURE 2 HUMAN MICROBIOME MARKET: BREAKDOWN OF PRIMARIES 30
2.2 MARKET ESTIMATION METHODOLOGY 30
FIGURE 3 MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ANALYSIS-BASED ESTIMATION), 2023 31
FIGURE 4 HUMAN MICROBIOME MARKET SIZE, 2023 (USD MILLION) 32
FIGURE 5 HUMAN MICROBIOME MARKET: FINAL CAGR PROJECTIONS (2023−2029) 32
FIGURE 6 HUMAN MICROBIOME MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 33
2.3 MARKET DATA ESTIMATION AND TRIANGULATION 34
2.3.1 DATA TRIANGULATION 34
FIGURE 7 DATA TRIANGULATION METHODOLOGY 34
2.4 INDUSTRY INSIGHTS 35
2.5 RESEARCH ASSUMPTIONS 35
2.6 HUMAN MICROBIOME MARKET: GLOBAL RECESSION IMPACT 36
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (% GROWTH) 36
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 36
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 36
3 EXECUTIVE SUMMARY 38
FIGURE 8 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023 VS. 2029 (USD MILLION) 38
FIGURE 9 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023 VS. 2029 (USD MILLION) 39

FIGURE 10 HUMAN MICROBIOME MARKET, BY DISEASE, 2023 VS. 2029 (USD MILLION) 39
FIGURE 11 HUMAN MICROBIOME MARKET: GEOGRAPHICAL SNAPSHOT 40
4 PREMIUM INSIGHTS 41
4.1 HUMAN MICROBIOME MARKET OVERVIEW 41
FIGURE 12 RISING FOCUS ON HUMAN MICROBIOME THERAPEUTICS DEVELOPMENT TO DRIVE GROWTH 41
4.2 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION AND COUNTRY (2023) 41
FIGURE 13 THERAPEUTICS SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2023 41
4.3 HUMAN MICROBIOME MARKET: GEOGRAPHICAL GROWTH OPPORTUNITIES 42
FIGURE 14 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 15 HUMAN MICROBIOME MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 43
TABLE 4 HUMAN MICROBIOME MARKET: IMPACT ANALYSIS 44
5.2.1 DRIVERS 44
5.2.1.1 Collaborative efforts between microbiome industry and academia for microbiome research 44
5.2.1.2 Surging demand for personalized medicine 45
5.2.1.3 Rising awareness about importance of human microbiome 45
5.2.2 RESTRAINTS 46
5.2.2.1 Adverse impact of complex regulatory policies on commercialization of microbiomes 46
5.2.3 OPPORTUNITIES 46
5.2.3.1 Increased collaboration of key players and small innovative companies to work on new microbiome technologies 46
TABLE 5 EXAMPLES OF COMPANY DEVELOPMENT 47
5.2.4 CHALLENGES 48
5.2.4.1 Slow patient adoption of microbiome-based therapies 48
5.2.4.2 Complexities involved in development of microbiome therapies 48
5.3 TECHNOLOGY ANALYSIS 49
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 51
FIGURE 16 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 51
5.5 SUPPLY AND VALUE CHAIN ANALYSIS 52
5.5.1 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 52
FIGURE 17 HUMAN MICROBIOME MARKET: SUPPLY CHAIN ANALYSIS 52
5.5.2 VALUE CHAIN ANALYSIS OF HUMAN MICROBIOME MARKET 53
FIGURE 18 HUMAN MICROBIOME MARKET: VALUE CHAIN ANALYSIS 53
5.6 ECOSYSTEM ANALYSIS 54
FIGURE 19 HUMAN MICROBIOME MARKET: ECOSYSTEM ANALYSIS 54
5.7 PORTER’S FIVE FORCES ANALYSIS 54
TABLE 6 HUMAN MICROBIOME MARKET: PORTER’S FIVE FORCES ANALYSIS 54
5.7.1 THREAT OF NEW ENTRANTS 54
5.7.2 THREAT OF SUBSTITUTES 54
5.7.3 BARGAINING POWER OF BUYERS 55
5.7.4 BARGAINING POWER OF SUPPLIERS 55
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 55
5.8 REGULATORY ANALYSIS 56
5.8.1 FDA APPROVALS 56
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 7 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 8 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 56
TABLE 9 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
TABLE 10 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 58
5.9 PRICING ANALYSIS 58
TABLE 11 AVERAGE SELLING PRICES OF KEY PLAYERS, BY PRODUCT 58
5.9.1 AVERAGE SELLING PRICE TREND ANALYSIS 58
5.10 KEY CONFERENCES AND EVENTS IN 2023 59
5.10.1 HUMAN MICROBIOME CONFERENCES (2023) 59
TABLE 12 HUMAN MICROBIOME CONFERENCES (2023) 59
5.11 KEY STAKEHOLDERS AND BUYING CRITERIA 60
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 60
FIGURE 20 HUMAN MICROBIOME MARKET: INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS 60
5.11.2 HUMAN MICROBIOME MARKET: BUYING CRITERIA 60
FIGURE 21 KEY BUYING CRITERIA FOR HEALTH SUPPLEMENTS AND MEDICAL FOODS 60
6 HUMAN MICROBIOME MARKET, BY APPLICATION 61
6.1 INTRODUCTION 62
TABLE 13 HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 62
6.2 THERAPEUTICS 62
6.2.1 AVAILABILITY OF FUNDING FOR DEVELOPMENT OF MICROBIOME-BASED THERAPEUTIC PRODUCTS TO DRIVE MARKET 62
TABLE 14 HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY REGION, 2023–2029 (USD MILLION) 64
TABLE 15 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 64
TABLE 16 EUROPE: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 64
TABLE 17 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR THERAPEUTICS, BY COUNTRY, 2023–2029 (USD MILLION) 65
6.3 DIAGNOSTICS 65
6.3.1 INCREASE IN FOCUS ON BIOMARKER-BASED DIAGNOSTIC TESTS TO DRIVE MARKET 65
TABLE 18 HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY REGION, 2023–2029 (USD MILLION) 66
TABLE 19 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 66
TABLE 20 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 67
TABLE 21 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTICS, BY COUNTRY, 2023–2029 (USD MILLION) 67
7 HUMAN MICROBIOME MARKET, BY DISEASE 68
7.1 INTRODUCTION 69
TABLE 22 HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 69
7.2 INFECTIOUS DISEASES 69
7.2.1 RISE IN CLINICAL STUDIES FOR CLOSTRIDIUM DIFFICILE INFECTION TO BOOST MARKET 69
TABLE 23 DEVELOPMENT OF MICROBIOME-BASED ANTI-BACTERIAL DRUGS FOR INFECTIOUS DISEASES 70
TABLE 24 HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY REGION, 2023–2029 (USD MILLION) 71
TABLE 25 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 71
TABLE 26 EUROPE: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 71
TABLE 27 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 72
7.3 GASTROINTESTINAL DISEASES 72
7.3.1 SPIKE IN CLINICAL STUDIES FOR GASTROINTESTINAL DISEASES TO PROPEL MARKET 72
TABLE 28 HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY REGION, 2023–2029 (USD MILLION) 72
TABLE 29 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
TABLE 30 EUROPE: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
TABLE 31 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR GASTROINTESTINAL DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 73
7.4 ENDOCRINE & METABOLIC DISORDERS 74
7.4.1 DEVELOPMENT OF MICROBIOME MODULATORS FOR TREATMENT OF METABOLIC DISORDERS TO BOOST MARKET 74
TABLE 32 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR ENDOCRINE & METABOLIC DISORDERS 74
TABLE 33 HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY REGION, 2023–2029 (USD MILLION) 75
TABLE 34 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 75
TABLE 35 EUROPE: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 75
TABLE 36 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR ENDOCRINE & METABOLIC DISORDERS, BY COUNTRY, 2023–2029 (USD MILLION) 76
7.5 CANCER 76
7.5.1 DEVELOPMENT OF MICROBIOME-BASED PRODUCTS FOR TREATMENT OF PELVIC AND COLON CANCER TO DRIVE MARKET 76
TABLE 37 HUMAN MICROBIOME MARKET FOR CANCER, BY REGION, 2023–2029 (USD MILLION) 77
TABLE 38 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 77
TABLE 39 EUROPE: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 77
TABLE 40 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR CANCER, BY COUNTRY, 2023–2029 (USD MILLION) 78
7.6 OTHER DISEASES 78
TABLE 41 HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY REGION, 2023–2029 (USD MILLION) 78
TABLE 42 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 78
TABLE 43 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 79
TABLE 44 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER DISEASES, BY COUNTRY, 2023–2029 (USD MILLION) 79
8 HUMAN MICROBIOME MARKET, BY PRODUCT 80
8.1 INTRODUCTION 81
TABLE 45 HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION)) 81
8.2 DRUGS 81
8.2.1 GROWING PIPELINE OF MICROBIOME-BASED DRUGS TO DRIVE MARKET 81
TABLE 46 HUMAN MICROBIOME MARKET FOR DRUGS, BY REGION, 2023–2029 (USD MILLION) 82
TABLE 47 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 82
TABLE 48 EUROPE: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 82
TABLE 49 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DRUGS, BY COUNTRY, 2023–2029 (USD MILLION) 83
8.3 DIAGNOSTIC TESTS 83
8.3.1 GROWING CONSUMER AWARENESS OF MICROBIOME-BASED TESTS TO BOOST MARKET 83
TABLE 50 HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY REGION, 2023–2029 (USD MILLION) 84
TABLE 51 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 84
TABLE 52 EUROPE: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 85
TABLE 53 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR DIAGNOSTIC TESTS, BY COUNTRY, 2023–2029 (USD MILLION) 85
8.4 PROBIOTICS 85
8.4.1 GROWING RESEARCH ON PROBIOTICS TO PROMOTE CREDIBILITY IN HEALTH CLAIMS AND SAFETY 85
TABLE 54 HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY REGION, 2023–2029 (USD MILLION) 86
TABLE 55 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 86
TABLE 56 EUROPE: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 87
TABLE 57 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PROBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 87
8.5 PREBIOTICS 87
8.5.1 DEVELOPMENT OF TARGETED PREBIOTICS TO DRIVE SEGMENTAL GROWTH 87
TABLE 58 HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY REGION, 2023–2029 (USD MILLION) 88
TABLE 59 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 88
TABLE 60 EUROPE: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 89
TABLE 61 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PREBIOTICS, BY COUNTRY, 2023–2029 (USD MILLION) 89
8.6 OTHER PRODUCTS 89
TABLE 62 HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2029 (USD MILLION) 90
TABLE 63 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 64 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 90
TABLE 65 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 91
9 HUMAN MICROBIOME MARKET, BY TYPE 92
9.1 INTRODUCTION 93
TABLE 66 HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 93
9.2 BACTERIAL CONSORTIA TRANSPLANTATION (BCT)/FECAL MICROBIOTA TRANSPLANTATION (FMT) 93
9.2.1 ADVANCEMENTS IN CLINICAL TRIALS FOR TREATMENT OF C. DIFFICILE INFECTION TO AUGMENT SEGMENTAL GROWTH 93
TABLE 67 HUMAN MICROBIOME MARKET FOR BCT/FMT, BY REGION, 2023–2029 (USD MILLION) 94
TABLE 68 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 94
TABLE 69 EUROPE: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 94
TABLE 70 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR BCT/FMT, BY COUNTRY, 2023–2029 (USD MILLION) 95
9.3 PEPTIDES 95
9.3.1 POTENTIAL OF PEPTIDES IN REDUCING NEURODEGENERATIVE DISORDERS TO DRIVE MARKET 95
TABLE 71 HUMAN MICROBIOME MARKET FOR PEPTIDES, BY REGION, 2023–2029 (USD MILLION) 96
TABLE 72 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 96
TABLE 73 EUROPE: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 96
TABLE 74 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR PEPTIDES, BY COUNTRY, 2023–2029 (USD MILLION) 97
9.4 LIVE BIOTHERAPEUTIC PRODUCTS 97
9.4.1 GROWING R&D INVESTMENTS FOR LIVE BIOTHERAPEUTIC PRODUCTS TO BOOST MARKET 97
TABLE 75 HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY REGION, 2023–2029 (USD MILLION) 98
TABLE 76 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 77 EUROPE: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 98
TABLE 78 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR LIVE BIOTHERAPEUTIC PRODUCTS, BY COUNTRY, 2023–2029 (USD MILLION) 99
9.5 OTHER TYPES 99
TABLE 79 HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY REGION, 2023–2029 (USD MILLION) 99
TABLE 80 NORTH AMERICA: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 81 EUROPE: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
TABLE 82 ASIA PACIFIC: HUMAN MICROBIOME MARKET FOR OTHER TYPES, BY COUNTRY, 2023–2029 (USD MILLION) 100
10 HUMAN MICROBIOME MARKET, BY REGION 101
10.1 INTRODUCTION 102
FIGURE 22 HUMAN MICROBIOME MARKET, BY REGION, 2023 VS. 2029 (USD MILLION) 102
TABLE 83 HUMAN MICROBIOME MARKET, BY REGION, 2023–2029 (USD MILLION) 102
10.2 NORTH AMERICA 103
FIGURE 23 NORTH AMERICA: HUMAN MICROBIOME MARKET SNAPSHOT 104
TABLE 84 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 104
TABLE 85 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 105
TABLE 86 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 105
TABLE 87 NORTH AMERICA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 105
10.2.1 US 106
10.2.1.1 Spike in research activities to drive market 106
TABLE 88 US: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 106
TABLE 89 US: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 107
TABLE 90 US: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 107
TABLE 91 US: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 107
10.2.2 CANADA 108
10.2.2.1 Rising prevalence of chronic diseases to boost microbiome research 108
TABLE 92 CANADA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 108
TABLE 93 CANADA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 108
TABLE 94 CANADA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 109
TABLE 95 CANADA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 109
10.2.3 NORTH AMERICA: RECESSION IMPACT 109
10.3 EUROPE 110
TABLE 96 EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 110
TABLE 97 EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 111
TABLE 98 EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 111
TABLE 99 EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 111
10.3.1 GERMANY 112
10.3.1.1 Rapid increase in government funding to propel market 112
TABLE 100 GERMANY: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 112
TABLE 101 GERMANY: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 112
TABLE 102 GERMANY: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 113
TABLE 103 GERMANY: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 113
10.3.2 UK 113
10.3.2.1 Significant government investments in genomics research to propel growth 113
TABLE 104 UK: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 114
TABLE 105 UK: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 114
TABLE 106 UK: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 114
TABLE 107 UK: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 115
10.3.3 FRANCE 115
10.3.3.1 Rise in microbiome sequencing startups to boost growth 115
TABLE 108 HUMAN MICROBIOME STARTUPS IN FRANCE 116
TABLE 109 FRANCE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 116
TABLE 110 FRANCE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 117
TABLE 111 FRANCE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 117
TABLE 112 FRANCE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 117
10.3.4 REST OF EUROPE 118
TABLE 113 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 118
TABLE 114 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 118
TABLE 115 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 119
TABLE 116 REST OF EUROPE: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 119
10.3.5 EUROPE: IMPACT OF RECESSION 119
10.4 ASIA PACIFIC 120
FIGURE 24 ASIA PACIFIC: HUMAN MICROBIOME MARKET SNAPSHOT 121
TABLE 117 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY COUNTRY, 2023–2029 (USD MILLION) 121
TABLE 118 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 122
TABLE 119 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 122
TABLE 120 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 122
TABLE 121 ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 123
10.4.1 CHINA 123
10.4.1.1 Increasing R&D investments to drive growth 123
TABLE 122 CHINA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 124
TABLE 123 CHINA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 124
TABLE 124 CHINA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 124
TABLE 125 CHINA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 125

10.4.2 JAPAN 125
10.4.2.1 Growing geriatric population to present opportunities for market growth 125
TABLE 126 JAPAN: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 126
TABLE 127 JAPAN: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 126
TABLE 128 JAPAN: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 126
TABLE 129 JAPAN: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 127
10.4.3 INDIA 127
10.4.3.1 Increasing prevalence of chronic diseases to support growth 127
TABLE 130 INDIA: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 128
TABLE 131 INDIA: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 128
TABLE 132 INDIA: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 128
TABLE 133 INDIA: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 129
10.4.4 REST OF ASIA PACIFIC 129
TABLE 134 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 129
TABLE 135 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 130
TABLE 136 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 130
TABLE 137 REST OF ASIA PACIFIC: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 130
10.4.5 ASIA PACIFIC: RECESSION IMPACT 131
10.5 REST OF THE WORLD 131
TABLE 138 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY PRODUCT, 2023–2029 (USD MILLION) 131
TABLE 139 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY DISEASE, 2023–2029 (USD MILLION) 132
TABLE 140 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY APPLICATION, 2023–2029 (USD MILLION) 132
TABLE 141 REST OF THE WORLD: HUMAN MICROBIOME MARKET, BY TYPE, 2023–2029 (USD MILLION) 132
10.5.1 REST OF THE WORLD: RECESSION IMPACT 133
11 COMPETITIVE LANDSCAPE 134
11.1 INTRODUCTION 134
11.2 KEY STRATEGIES ADOPTED BY PLAYERS 134
FIGURE 25 HUMAN MICROBIOME MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 135

11.3 COMPANY EVALUATION QUADRANT 136
FIGURE 26 HUMAN MICROBIOME MARKET: COMPANY EVALUATION MATRIX (2022) 137
11.3.1 STARS 138
11.3.2 EMERGING LEADERS 138
11.3.3 PERVASIVE PLAYERS 138
11.3.4 PARTICIPANTS 138
11.4 COMPANY EVALUATION QUADRANT: START-UPS/SMES 139
11.4.1 PROGRESSIVE COMPANIES 139
11.4.2 STARTING BLOCKS 139
11.4.3 RESPONSIVE COMPANIES 139
11.4.4 DYNAMIC COMPANIES 139
FIGURE 27 HUMAN MICROBIOME MARKET: START-UPS/SMES EVALUATION QUADRANT (2022) 140
11.4.5 COMPETITIVE BENCHMARKING 141
11.4.5.1 Human microbiome market: Detailed list of start-ups/SMEs 141
TABLE 142 HUMAN MICROBIOME MARKET: DETAILED LIST OF START-UPS/SMES 141
11.4.5.2 Human microbiome market: Competitive benchmarking of key players (start-ups/SMEs) 142
TABLE 143 HUMAN MICROBIOME MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS (START-UPS/SMES) 142
11.5 COMPETITIVE SCENARIO AND TRENDS 142
TABLE 144 HUMAN MICROBIOME MARKET: DEALS 142
11.5.1 PRODUCT LAUNCHES 144
TABLE 145 HUMAN MICROBIOME MARKET: PRODUCT LAUNCHES 144
11.5.2 EXPANSIONS 144
TABLE 146 HUMAN MICROBIOME MARKET: EXPANSIONS 144
12 COMPANY PROFILES 145
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS 145
12.1.1 SERES THERAPEUTICS, INC. 145
TABLE 147 SERES THERAPEUTICS, INC.: COMPANY OVERVIEW 145
12.1.2 ENTEROME 148
TABLE 148 ENTEROME: COMPANY OVERVIEW 148
12.1.3 4D PHARMA PLC 151
TABLE 149 4D PHARMA: COMPANY OVERVIEW 151
FIGURE 29 4D PHARMA: COMPANY SNAPSHOT (2022) 151
12.1.4 INTERNATIONAL FLAVORS & FRAGRANCES, INC. 154
TABLE 150 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY OVERVIEW 154
FIGURE 30 INTERNATIONAL FLAVORS & FRAGRANCES INC.: COMPANY SNAPSHOT (2022) 155

12.1.5 OPTIBIOTIX HEALTH PLC 157
TABLE 151 OPTIBIOTIX: COMPANY OVERVIEW 157
FIGURE 31 OPTIBIOTIX: COMPANY SNAPSHOT (2021) 158
12.1.6 FERRING PHARMACEUTICALS 162
TABLE 152 FERRING PHARMACEUTICALS: COMPANY OVERVIEW 162
12.1.7 SYNLOGIC, INC. 163
TABLE 153 SYNLOGIC, INC.: COMPANY OVERVIEW 163
FIGURE 32 SYNLOGIC, INC: COMPANY SNAPSHOT (2022) 163
12.1.8 SECOND GENOME INC. 165
TABLE 154 SECOND GENOME INC.: COMPANY OVERVIEW 165
12.1.9 VEDANTA BIOSCIENCES, INC. 167
TABLE 155 VEDANTA BIOSCIENCES: COMPANY OVERVIEW 167
12.1.10 YSOPIA BIOSCIENCE 169
TABLE 156 YSOPIA BIOSCIENCE: COMPANY OVERVIEW 169
12.1.11 FLIGHTPATH BIOSCIENCES, INC. 170
TABLE 157 FLIGHTPATH BIOSCIENCES, INC.: COMPANY OVERVIEW 170
12.1.12 FINCH THERAPEUTICS GROUP, INC. 171
TABLE 158 FINCH THERAPEUTICS: COMPANY OVERVIEW 171
FIGURE 33 FINCH THERAPEUTICS: COMPANY SNAPSHOT (2022) 171
12.1.13 AOBIOME THERAPEUTICS 172
TABLE 159 AOBIOME THERAPEUTICS: COMPANY OVERVIEW 172
12.1.14 BIOGAIA 173
TABLE 160 BIOGAIA: COMPANY OVERVIEW 173
FIGURE 34 BIOGAIA: COMPANY SNAPSHOT (2021) 174
12.1.15 QUANTBIOME, INC. (DBA OMBRE) 177
TABLE 161 QUANTBIOME, INC.: COMPANY OVERVIEW 177
12.2 OTHER PLAYERS 178
12.2.1 VIOME LIFE SCIENCES, INC. 178
12.2.2 BIOHM HEALTH 178
12.2.3 DAYTWO 179
12.2.4 ALTAS BIOMED 179
12.2.5 BIONE VENTURES PRIVATE LIMITED 180
12.2.6 LUXIA SCIENTIFIC 180
12.2.7 METABIOMICS 181
12.2.8 SUN GENOMICS 181
12.2.9 SEED HEALTH 182
12.2.10 GNUBIOTICS SCIENCES 182
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.

13 APPENDIX 183
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 186
13.2 CUSTOMIZATION OPTIONS 188
13.3 RELATED REPORTS 188
13.4 AUTHOR DETAILS 189

ページTOPに戻る

Table of Contents

Summary

The human microbiome market is projected to reach USD 1.7 billion by 2029 from USD 0.3 billion in 2023, at a CAGR of 36.1% during the forecast period. The key factors driving the growth of the human microbiome market are the surging demand for personalized medicine, and growing demand for natural and holistic approaches is expected to propel the growth of the market. However, limited understanding of microbial interactions are expected to restrain market growth to a certain extent.
The human microbiome market has been segmented based on product, type, application, disease, and region.
“By application, the therapeutics segment accounted for the largest share of the human microbiome market”
Based on application, the human microbiome market is categorized into therapeutics, and diagnostics. The therapeutics segment dominated the market in 2023, owing to the increasing understanding of the crucial role that the microbiome plays in maintaining human health. It is also driven by increasing investment from pharmaceutical and biotechnology companies and the growing demand for personalized medicine.
“By disease, infectious diseases segment accounted for the largest share in the human microbiome market”
Based on disease, the human microbiome market is segmented into infectious diseases, endocrine & metabolic disorders, gastrointestinal diseases, cancer, and other diseases. In 2023, the infectious diseases segment accounted for a larger share of the human microbiome market. Growth in this market segment can be attributed to increasing understanding of the role of the microbiome in human health and the development of advanced sequencing and bioinformatics techniques are paving the way for the discovery and characterization of novel microbiome-based therapeutics for the prevention and treatment of infectious diseases.

“North America: the largest share of the human microbiome market”
North America accounted for the largest share of the human microbiome market. The large share of the North America region can be attributed to a well-established healthcare and biotechnology industry in the region, with advanced infrastructure, cutting-edge research institutions, and a strong ecosystem of biotechnology companies and CROs specializing in microbiome research. The presence of top academic institutions, research hospitals, and private companies in North America with dedicated microbiome research programs and expertise has contributed to the growth of the human microbiome market.
“Asia Pacific: The fastest-growing region in the human microbiome market.”
The Asia Pacific human microbiome market is projected to grow at the highest CAGR during the forecast period. This is attributed to increasing awareness of the importance of the microbiome in health and disease, the rising demand for personalized medicine, and advancements in sequencing technologies. Another key driver for the Asia Pacific human microbiome market is the region's large and rapidly aging population.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 60% and Demand Side 40%
• By Designation: Executives - 40%, Research Scientists- 30%, and Managers - 30%
• By Country: North America- 22%, Europe- 42%, Asia Pacific- 11%, Rest of the World- 25%

Prominent Players
• Seres Therapeutics, Inc. (US)
• Enterome (France)
• 4D pharma plc (UK)
• International Flavors & Fragrances Inc. (US)
• OptiBiotix Health Plc (UK)
• Ferring Pharmaceuticals (Switzerland)
• Synlogic, Inc. (US)
• Second Genome, Inc. (US)
• Vedanta Biosciences, Inc. (US)
• YSOPIA Bioscience (France)
• FlightPath Biosciences, Inc. (US)
• Finch Therapeutics Group, Inc. (US)
• AOBiome Therapeutics (US)
• BioGaia (Sweden)
• Quantbiome, Inc. (dba Ombre) (US)
• Viome Life Sciences, Inc. (US)
• BIOHM Health (US)
• DayTwo (US)
• Atlas Biomed (UK)
• Bione Ventures Private Limited (India)
• Luxia Scientific (France)
• Metabiomics (US)
• Sun Genomics (US)
• Seed Health (US)
• Gnubiotics Sciences (Switzerland)
Research Coverage:
This report provides a detailed picture of the human microbiome market. It aims at estimating the size and future growth potential of the market across different segments, such as the product (drugs, diagnostics tests, probiotics, prebiotics, and other products), application (therapeutic, and diagnostics), disease (infectious diseases, gastrointestinal diseases, endocrine & metabolic diseases, cancer, and other diseases), type (Bacterial consortia transplantation (BCT)/ fecal microbiota transplantation(FMT), peptides, live biotherapeutic products, and other types), and region (North America, Europe, Asia Pacific, and Rest of the World). The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall human microbiome market and its segments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
The report provide insights on the following pointers”
• Analysis of key drivers (collaborative efforts between microbiome industry and academia for microbiome research, surging demand for personalized medicine, and rising awareness about importance of human microbiome), restraints (adverse impact of complex regulatory policies on commercialization of microbiomes), opportunities (increased collaboration of key players and small innovative companies collaborating to work on new microbiome technologies, and advancements in sequencing and bioinformatics), and challenges (low patient adoption rate of microbiome-based therapies, and complexities involved in development of microbiome therapies) influencing the growth of the human microbiome market.
• Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the human microbiome market.
• Market Development: Comprehensive information about lucrative markets- the report analyses the human microbiome market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the human microbiome market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies and service offerings of leading players like Seres Therapeutics, Inc. (US), Enterome (France), 4D pharma plc (UK), International Flavors & Fragrances Inc. (US), and OptiBiotix Health Plc (UK) among others in the human microbiome market strategies. The report also helps stakeholders understand the pulse of the animal research model market and provides them information on key market drivers, restraints, challenges and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

ヒトマイクロバイオーム市場：製品（医薬品、プロバイオティクス、プレバイオティクス）、用途（治療、診断）、疾患（がん、消化器、感染症）、タイプ（ペプチド、生きたバイオ治療製品、FMT） - 2029年までの世界予測

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（バイオ薬物）の最新刊レポート

MarketsandMarkets社のBiotechnology分野での最新刊レポート

本レポートと同じKEY WORD（diagnostics）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?